6:30 AM SIGN-IN & BREAKFAST • 7:00 AM - 8:30 AM
BANDOL 2 (NEW WYNN SPACE)
CE: Myelodysplastic Syndrome and Myelodysplastic-associated Anemia: Exploring Clinical Treatment Updates
Myelodysplastic syndromes (MDSs) are a group of relatively rare heterogeneous diseases that affect the blood and bone marrow. Anemia is one of the most common findings in MDS, often requiring blood transfusions to improve quality of life and patient outcomes. Consequences of transfusions include iron overload, necessitating the use of iron chelators. An agent with a new erythroid maturation mechanism has been approved in the past 12 months and additional agents with promising outcomes are in the pipeline. These agents could mitigate the need for transfusions, thereby diminishing the consequences of iron overload in this patient population. This program will examine MDS, the complications of MDS-associated anemia, and innovative treatments for addressing this clinical need. Discussion will include addressing the considerable economic burden of MDS as direct medical resource utilization and treatment and supportive care costs, such as red blood cell transfusions, account for a significant portion of MDS-related costs.